Investigational drug · Phase 2
Autologous Tumor Infiltrating Lymphocytes
Also called: GC101 TIL
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non Small Cell Lung Cancer, Melanoma.
Phase 2Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
167
Any phase or sponsor naming "Autologous Tumor Infiltrating Lymphocytes"
First trial start
2024
Dec 20, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Autologous Tumor Infiltrating Lymphocytes", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non Small Cell Lung Cancer
- Melanoma
Approved drugs for the same conditions: Small cell lung cancer · Melanoma · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Autologous Tumor Infiltrating Lymphocytes" as an intervention, largest first.
- Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.Pivotal-lookingRecruiting
Iovance Biotherapeutics, Inc.Industry
NCT05727904 · 670 participants (planned) · Start Mar 30, 2023 · Primary completion Mar 1, 2028
Drug: Lifileucel plus Pembrolizumab; Pembrolizumab with Optional Crossover Period · For: Metastatic Melanoma; Unresectable Melanoma; Melanoma
Sites: Birmingham, Alabama; Duarte, California; Los Angeles, California · 82 sites in all
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)Not yet recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07307053 · 600 participants (planned) · Start Jan 1, 2026 · Primary completion Jan 31, 2029
Drug: BL-B01D1; VSV injection and 18 more · For: Rare Malignant Neoplasm; Advanced Solid Tumors; Metastatic Solid Tumors
National Cancer Institute (NCI)NIH
NCT01174121 · 332 participants (planned) · Start Aug 26, 2010 · Primary completion Dec 27, 2028
Drug: Pembrolizumab (Keytruda); Fludarabine and 3 more · For: Metastatic Colorectal Cancer; Metastatic Pancreatic Cancer; Metastatic Ovarian Cancer and 2 more
Sites: Bethesda, Maryland
Obsidian Therapeutics, Inc.Industry
NCT06060613 · 254 participants (planned) · Start Oct 25, 2023 · Primary completion Jun 30, 2029
Drug: OBX-115 · For: Tumor Skin; Metastatic Melanoma; Melanoma and 4 more
Sites: Tucson, Arizona; Los Angeles, California; Stanford, California · 14 sites in all
Iovance Biotherapeutics, Inc.Industry
NCT03645928 · 225 participants · Start May 7, 2019 · Primary completion Feb 20, 2026
Drug: Lifileucel; LN-145 and 10 more · For: Metastatic Melanoma; Squamous Cell Carcinoma of the Head and Neck; Non-small Cell Lung Cancer
Sites: La Jolla, California; Los Angeles, California; Denver, Colorado · 34 sites in all
Iovance Biotherapeutics, Inc.Industry
NCT02360579 · 220 participants · Start Sep 24, 2015 · Primary completion Oct 24, 2024
Drug: Lifileucel · For: Metastatic Melanoma
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 57 sites in all
Iovance Biotherapeutics, Inc.Industry
NCT03108495 · 210 participants · Start Jun 22, 2017 · Primary completion Aug 22, 2025
Drug: LN-145; LN-145 + pembrolizumab · For: Cervical Carcinoma
Sites: Phoenix, Arizona; Los Angeles, California; San Diego, California · 43 sites in all
Iovance Biotherapeutics, Inc.Industry
NCT04614103 · 170 participants (planned) · Start May 7, 2021 · Primary completion Dec 2030
Drug: LN-145; LN-145 · For: Metastatic Non Small Cell Lung Cancer
Sites: Gilbert, Arizona; Miami, Florida; Tampa, Florida · 71 sites in all
National Cancer Institute (NCI)NIH
NCT00513604 · 158 participants · Start Jun 2007 · Primary completion Nov 2012
Drug: aldesleukin; therapeutic autologous lymphocytes and 2 more · For: Melanoma; Malignant Melanoma; Melanoma, Experimental and 1 more
Sites: Bethesda, Maryland
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06598371 · 141 participants (planned) · Start Nov 21, 2024 · Primary completion Aug 1, 2039
Drug: Cyclophosphamide; Fludarabine and 2 more · For: Select Advanced Solid Tumors
Sites: Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Pleiotropic effects of BET inhibition broadly boost tumor immunogenicity to CD8+ T cells.
Melief J, Baldran-Groves L, Gerault MA, et al. · Oncoimmunology 2026
- LM103, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced melanoma resistant to standard therapy.
Zhou L, Cai X, Du H, et al. · Cancer Immunol Res 2026
- Analysis of the tumor reactivity of autologous TILs and allogeneic γδ T cells via tumor organoid-immune cell coculture.
Su Z, Li H, Zhang D, et al. · J Transl Med 2026
- Phase I trial of locoregional administration of autologous tumor-infiltrating lymphocytes in patients with uveal melanoma and liver metastases (the HAITILS trial).
Nelson A, Riise R, Alsén S, et al. · J Immunother Cancer 2026
- Discover personalized drug opportunity and optimized tumor-infiltrating lymphocyte therapy for rare cancer: an organoid-based whole-journey clinical mapping study in a neuroendocrine cancer patient.
Gao X, Liu Z, Xu Z, et al. · Cell Oncol (Dordr) 2026
- Patient-derived models of tumor-immune cell interactions.
Nemati N, Boeck N, Trajanoski Z · Methods Cell Biol 2026
Also in development for Non Small Cell Lung Cancer
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- DomvanalimabAB154, GS-0154Phase 310 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- SI-B001Phase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- TucidinostatChidamide, HBI-8000Phase 39 trials
Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
- LBL-007AlcestobartPhase 38 trials
BeOne Medicines (BeiGene) · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
- aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials
Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.